Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies

ISSN: 1874-4729 (Online)
ISSN: 1874-4710 (Print)


Volume 7, 2 Issues, 2014


Download PDF Flyer




Current Radiopharmaceuticals

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Sean L. Kitson
Current Radiopharmaceuticals
Radiochemistry
Almac Sciences
Almac House
20 Seagoe Industrial Estate
Craigavon, BT63 5QD
Northern Ireland


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies

Author(s): Giorgio Treglia, Luca Ceriani and Luca Giovanella

Affiliation: Department of Nuclear Medicine and PET/CT Center, Ente Ospedaliero Cantonale Street: via Ospedale, 12; zip code: 6500; city: Bellinzona; country: Switzerland

Abstract

Dementia with Lewy bodies (DLB) is the second most common cause of degenerative dementia after Alzheimer’s disease (AD). To improve the diagnosis of DLB, the latest diagnostic criteria incorporate findings from neuroimaging studies including sympathetic innervation imaging with iodine-123-metaiodobenzylguanidine (MIBG). According to these criteria a decreased MIBG myocardial uptake is an important finding supporting a clinical diagnosis of DLB. In this review the state of art and future perspectives of sympathetic innervation imaging by using MIBG in the diagnosis of DLB are discussed

Keywords: MIBG, metaiodobenzylguanidine, dementia with Lewy bodies, dementia, innervation imaging

Purchase Online Rights and Permissions

Article Details

Volume: 7
First Page: 1
Last Page: 4
Page Count: 4
DOI: 10.2174/1874471007666140314094323
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science